overhyped and very risky, page-7

I don't think you'll see 50c again, I don't even think you'll see sub $2 for long. Biota is on a winner with Relenza and LANI... only a matter for time for the market to realise this. BTA was so poorly priced that it traded at it's net cash backing, or even below. Aussies just don't know how to value biotechs, they rather stare at charts trying to predict patterns where no patterns exist.